| Summary of Basic and Diluted Loss Per Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(131,999 |
) |
|
$ |
(82,175 |
) |
|
$ |
(262,444 |
) |
|
$ |
(224,370 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding, basic and diluted |
|
|
84,281,989 |
|
|
|
71,485,033 |
|
|
|
82,797,025 |
|
|
|
67,270,902 |
|
Weighted average pre-funded warrants outstanding, basic and diluted |
|
|
15,815,253 |
|
|
|
15,815,253 |
|
|
|
15,815,253 |
|
|
|
15,382,240 |
|
Total weighted average common stock outstanding, basic and diluted |
|
|
100,097,242 |
|
|
|
87,300,286 |
|
|
|
98,612,278 |
|
|
|
82,653,142 |
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(1.32 |
) |
|
$ |
(0.94 |
) |
|
$ |
(2.66 |
) |
|
$ |
(2.71 |
) |
|
| Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect |
The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at September 30, 2026 and 2025 because including them would have had an anti-dilutive effect:
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30, |
|
|
|
2026 |
|
|
2025 |
|
Unvested restricted stock |
|
|
1,501,129 |
|
|
|
1,366,012 |
|
Options to purchase common stock |
|
|
8,629,352 |
|
|
|
10,543,593 |
|
Total |
|
|
10,130,481 |
|
|
|
11,909,605 |
|
|